Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & PTC Therapeutics (NASDAQ:PTCT)

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) and PTC Therapeutics (NASDAQ:PTCTGet Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Sarepta Therapeutics and PTC Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics 0 3 12 0 2.80
PTC Therapeutics 5 5 3 0 1.85

Sarepta Therapeutics currently has a consensus target price of $158.38, indicating a potential upside of 22.34%. PTC Therapeutics has a consensus target price of $33.53, indicating a potential upside of 15.27%. Given Sarepta Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Sarepta Therapeutics is more favorable than PTC Therapeutics.

Valuation & Earnings

This table compares Sarepta Therapeutics and PTC Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sarepta Therapeutics $1.24 billion 9.78 -$535.98 million ($6.12) -21.15
PTC Therapeutics $937.82 million 2.38 -$626.60 million ($8.36) -3.48

Sarepta Therapeutics has higher revenue and earnings than PTC Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sarepta Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Sarepta Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sarepta Therapeutics -43.11% -18.97% -4.65%
PTC Therapeutics -66.82% N/A -32.06%

Insider and Institutional Ownership

86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.4% of Sarepta Therapeutics shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats PTC Therapeutics on 12 of the 14 factors compared between the two stocks.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.